| scholarly article | Q13442814 |
| P50 | author | Liwei Lu | Q73014396 |
| P2093 | author name string | Chang Liu | |
| Songtao Shi | |||
| Xiang Gao | |||
| Lingyun Sun | |||
| Wanjun Chen | |||
| Haijun Ma | |||
| Zhuoya Zhang | |||
| Minghao Guo | |||
| Bingyu Shi | |||
| Ruihai Feng | |||
| P2860 | cites work | Mesenchymal stem cells and immunomodulation: current status and future prospects | Q26770191 |
| Potential serum and urine biomarkers in patients with lupus nephritis and the unsolved problems | Q28071798 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Complement: a key system for immune surveillance and homeostasis | Q29615484 | ||
| Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities | Q33393852 | ||
| Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab | Q33419007 | ||
| Of mice and men: The factor H protein family and complement regulation. | Q33421580 | ||
| Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy | Q33425891 | ||
| Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study | Q33767123 | ||
| Identification of a potent and orally active non-peptide C5a receptor antagonist | Q34154819 | ||
| The classification of glomerulonephritis in systemic lupus erythematosus revisited | Q34293066 | ||
| Complement factor H deficiency accelerates development of lupus nephritis | Q34534879 | ||
| Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice | Q34537391 | ||
| Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis | Q34627394 | ||
| Mesenchymal stem cells inhibit complement activation by secreting factor H. | Q35106559 | ||
| Complement and autoimmune glomerular diseases | Q35627102 | ||
| American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis | Q36221407 | ||
| Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. | Q37017177 | ||
| Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans | Q37246560 | ||
| Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. | Q37410508 | ||
| Complement related kidney diseases: Recurrence after transplantation | Q37522557 | ||
| Complement factor H-ligand interactions: self-association, multivalency and dissociation constants. | Q37964102 | ||
| Mesenchymal stem cell-educated macrophages | Q38078103 | ||
| Hematopoetic and mesenchymal stem cell transplantation in the treatment of refractory systemic lupus erythematosus--where are we now? | Q38081629 | ||
| Clinical presentation of human C1q deficiency: How much of a lupus? | Q38407945 | ||
| The Complement System in Lupus Nephritis | Q38634784 | ||
| The dysfunctions of complement factor H in lupus nephritis | Q38779138 | ||
| Remission and withdrawal of therapy in lupus nephritis. | Q38826018 | ||
| C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease | Q38909638 | ||
| Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence | Q38930294 | ||
| Treatments for Lupus Nephritis: A Systematic Review and Network Metaanalysis | Q38944067 | ||
| Complement factor H in host defense and immune evasion. | Q39036058 | ||
| Systemic lupus erythematosus biomarkers: the challenging quest | Q39053118 | ||
| Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice | Q40607655 | ||
| Interactions of complement proteins C1q and factor H with lipid A and Escherichia coli: further evidence that factor H regulates the classical complement pathway | Q42119300 | ||
| All Things Complement | Q42386506 | ||
| Complement activation by phospholipids: the interplay of factor H and C1q. | Q42772365 | ||
| Eculizumab as rescue therapy in severe resistant lupus nephritis. | Q43177789 | ||
| Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients. | Q43743664 | ||
| Combined oral contraceptives in women with systemic lupus erythematosus | Q46851436 | ||
| An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. | Q51730313 | ||
| The pathogenesis of lupus nephritis. | Q51868414 | ||
| MicroRNA-130b Ameliorates Murine Lupus Nephritis Through Targeting the Type I Interferon Pathway on Renal Mesangial Cells. | Q53125757 | ||
| Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies | Q57089602 | ||
| CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients | Q71537257 | ||
| Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells | Q71793631 | ||
| IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology | Q73149267 | ||
| Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice | Q73850612 | ||
| Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus | Q84311000 | ||
| Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study | Q84586351 | ||
| Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis | Q84892882 | ||
| Complement--tapping into new sites and effector systems | Q85959086 | ||
| P921 | main subject | mesenchymal stem cell | Q1922379 |
| P304 | page(s) | 21-30 | |
| P577 | publication date | 2018-06-07 | |
| P1433 | published in | EBioMedicine | Q24912341 |
| P1476 | title | Mesenchymal Stem Cells Control Complement C5 Activation by Factor H in Lupus Nephritis | |
| P478 | volume | 32 |
| Q92558817 | Curcumin mitigates the epithelial-to-mesenchymal transition in biliary epithelial cells through upregulating CD109 expression |
| Q89530746 | Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis |
| Q97067624 | IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production |
| Q99562886 | Potential of Extracellular Vesicle-Associated TSG-6 from Adipose Mesenchymal Stromal Cells in Traumatic Brain Injury |
| Q64922442 | Transplantation of dental tissue-derived mesenchymal stem cells ameliorates nephritis in lupus mice. |
Search more.